Company: DVAX
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001029142-25-000071
Chunk: 285

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 8
Chunk 285
---
Other segment items includes the net of: bad debt expense, interest income, interest expense, sublease income, loss on debt extinguishment, other expenses, and Benefit from income taxes, as presented on the face of our condensed consolidated statements of operations.(3)Net loss is our reported measure of segment profit or loss.

20

Table of Contents

9. Revenue Recognition 

Disaggregation of RevenuesThe following table disaggregates our product revenue, net by product and geographic region and disaggregates our other revenues by geographic region (in thousands): Three Months EndedMarch 31, 2025Three Months EndedMarch 31, 2024 U.S.Non U.S.TotalU.S.Non U.S.TotalProduct revenue, net     HEPLISAV-B$64,959 $- $64,959 $46,699 $1,146 $47,845 Total product revenue, net64,959 - 64,959 46,699 1,146 47,845 Other revenue2,847 358 3,205 2,802 143 2,945 Total revenues$67,806 $358 $68,164 $49,501 $1,289 $50,790 Revenues from Major Customers and Collaboration PartnersHEPLISAV-B product sales in the U.S. are to certain wholesalers and specialty distributors whose principal customers include integrated delivery networks, retail pharmacies, independent hospitals and clinics, public health clinics and prisons, the Department of Defense, and the Department of Veterans Affairs. HEPLISAV-B product sales in Germany are to one distributor. The following table summarizes HEPLISAV-B product revenue from each of our three largest customers (as a percentage of total HEPLISAV-B net product revenue): Three Months EndedMarch 31, 20252024Largest customer31 %27 %Second largest customer20 %19 %Third largest customer18 %18 %Contract BalancesThe following table summarizes balances and activities in HEPLISAV-B product revenue allowance and reserve categories for the three months ended March 31, 2025 (in thousands): Balance atBeginningof PeriodProvisionsrelated tocurrentperiod salesCredit orpaymentsmade duringthe periodAdjustments (3)Balanceat End ofPeriodThree months ended March 31, 2025:Accounts receivable reserves (1)$9,317 $19,695 $(19,034)$21